Regeneron Pharmaceuticals (REGN) Change in Acquisitions & Divestments (2009 - 2026)

Regeneron Pharmaceuticals' Change in Acquisitions & Divestments history runs 18 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 24.63% year-over-year to $2.6 billion in Q1 2026; TTM through Mar 2026 was $10.7 billion, a 25.49% decrease from a year earlier, with the FY2025 full-year figure at $11.5 billion, down 23.17% from the prior year.
• Change in Acquisitions & Divestments rose to $2.6 billion in Q1 2026 per REGN's latest filing, from $2.6 billion in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $4.3 billion in Q3 2024 and bottomed at $746.3 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $2.6 billion (2025), against an average of $2.6 billion.
• Across the five-year window, Change in Acquisitions & Divestments soared 383.46% in 2022 and plunged 46.53% in 2025, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $1.5 billion in 2022, then surged by 55.0% to $2.4 billion in 2023, then grew by 8.36% to $2.6 billion in 2024, then dropped by 1.05% to $2.6 billion in 2025, then advanced by 2.02% to $2.6 billion in 2026.
• Per Business Quant, the three latest REGN Change in Acquisitions & Divestments figures stand at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $3.4 billion (Q3 2025).